Press Releases

Press Releases

Date Title
May 1, 2021
UNITY Biotechnology Presents UBX1325 Data Demonstrating Improvement in Retinal Vasculature and Function in Preclinical Models of Diabetic Retinopathy Eye Diseases
UBX1325’s selective elimination of senescent cells represents a novel approach for the treatment of diabetic retinopathy and macular edema Preclinical data featured in poster presentations at the ARVO 2021 Annual Meeting SOUTH SAN FRANCISCO, Calif. , May 01, 2021 (GLOBE NEWSWIRE) -- UNITY
April 28, 2021
UNITY Biotechnology to Present Preclinical Data on Clinical Candidate Molecule UBX1325 at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting
SOUTH SAN FRANCISCO, Calif. , April 28, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, will present preclinical data on its lead clinical candidate, UBX1325, at the Association
April 21, 2021
UNITY Biotechnology Reports Granting of New Employment Inducement Awards
SOUTH SAN FRANCISCO, Calif. , April 21, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that from April 6, 2021 through April 20, 2021 , the Compensation Committee
March 23, 2021
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Business Updates
SOUTH SAN FRANCISCO, Calif. , March 23, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the fourth quarter and full year ended December 31, 2020
March 11, 2021
UNITY Biotechnology Reports Granting of New Employment Inducement Award
SOUTH SAN FRANCISCO, Calif. , March 11, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that Alexander Nguyen has officially joined UNITY as general counsel, and
March 8, 2021
UNITY Biotechnology Announces Appointment of Alexander Nguyen as General Counsel
SOUTH SAN FRANCISCO, Calif. , March 08, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that Alexander Nguyen has been appointed general counsel.
February 26, 2021
UNITY Biotechnology to Participate in Upcoming March Investor Conferences
SOUTH SAN FRANCISCO, Calif. , Feb. 26, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that members of its senior management team will participate in the following
February 24, 2021
UNITY Biotechnology Reports Granting of New Employment Inducement Awards
SOUTH SAN FRANCISCO, Calif. , Feb. 24, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that from February 9, 2021 through February 23, 2021 , the Board of
February 8, 2021
Study published in Cell Metabolism Reveals New Therapeutic Approach Aimed at Restoring Vascular Health and Reversing Age-Related Eye Disease
Study shows that senescent cells accumulate in the eye of patients with diabetic retinopathy, and elimination of these cells in preclinical models ameliorates disease Researchers at UNITY Biotechnology and University of Montreal provide mechanistic evidence supporting potential for vascular
February 3, 2021
UNITY Biotechnology Reports Granting of New Employment Inducement Awards
SOUTH SAN FRANCISCO, Calif. , Feb. 03, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that from January 19, 2021 through February 2, 2021 , the Board of Directors
Displaying 1 - 10 of 11